Cargando…

Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma

Chemo-immunotherapy has improved survival in B-cell lymphoma patients, but refractory/relapsed diseases still represent a major challenge, urging for development of new therapeutics. Karonudib (TH1579) was developed to inhibit MTH1, an enzyme preventing oxidized dNTP-incorporation in DNA. MTH1 is hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Oksvold, Morten P., Berglund, Ulrika Warpman, Gad, Helge, Bai, Baoyan, Stokke, Trond, Rein, Idun Dale, Pham, Therese, Sanjiv, Kumar, Øy, Geir Frode, Norum, Jens Henrik, Smeland, Erlend B., Myklebust, June H., Helleday, Thomas, Våtsveen, Thea Kristin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973795/
https://www.ncbi.nlm.nih.gov/pubmed/33737576
http://dx.doi.org/10.1038/s41598-021-85613-8